Suggested remit: To appraise the clinical and cost effectiveness of palopegteriparatide within its marketing authorisation for treating hypoparathyroidism.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process STA Standard
ID number 6380

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 May 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
15 March 2024 - 16 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6380
15 March 2024 In progress
09 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual